Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany

The TNF inhibitor golimumab (GLM) is a treatment option in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). The GO-NICE study assessed patient-reported outcomes (PRO) in patients newly treated with monthly GLM 50 mg subcutaneously (SC) under real-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Krüger, Klaus, Burmester, Gerd R., Wassenberg, Siegfried, Bohl-Bühler, Martin, Thomas, Matthias H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Patient Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329737/
https://www.ncbi.nlm.nih.gov/pubmed/30415451
http://dx.doi.org/10.1007/s00296-018-4180-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329737/
https://www.ncbi.nlm.nih.gov/pubmed/30415451
http://dx.doi.org/10.1007/s00296-018-4180-4

Ejemplares similares